MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    A systematic review to compare the effect of bilateral deep brain stimulation (STN versus GPI) on gait and balance in Parkinson’s disease

    D. Dash, D. Vibha, T. Mestre (Ottawa, Canada)

    Objective: To compare the effect of bilateral sub-thalamic nucleus (STN)  deep brain stimulation (DBS) and Globus pallidus interna (GPI) DBS on gait and postural stability in Parkinson’s…
  • 2022 International Congress

    Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, S. Bataga, R. Neagoe, J. Szederjesi, B. Grigorescu, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

    Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…
  • 2022 International Congress

    Embodied language in Parkinson disease: the case of demonstrative

    C. Giacobbe, Y. Coello, G. Santangelo (Caserta, Italy)

    Objective: Action language is recognized as impaired in Parkinson's disease (PD), proposing a functional role for the motor system in understanding action words [1]. This…
  • 2022 International Congress

    The benefit of exclusive nocturnal administration of a levodopa-carbidopa intestinal infusion for severe refractory sleep behavior disorder in Parkinson’s disease

    M. Rivera Sánchez, A. Sánchez Rodríguez, M. Sierra, I. González-Aramburu, MV. Sánchez Peláez, M. Martínez, J. Infante (Santander, Spain)

    Objective: Treatment by continuous diurnal intestinal infusion of levodopa is effective in improving sleep quality in Parkinson's disease (PD), but its use exclusively at night…
  • 2022 International Congress

    Estimating the Meaningful Within-Patient Change Threshold for the MDS-UPDRS Part III

    S. Zanigni, D. Trundell, A. Monnet, N. Shariati, E. Moore, E. Davies, N. Pross, G. Pagano, T. Nikolcheva (Basel, Switzerland)

    Objective: To estimate the meaningful within-patient worsening threshold (MWPWT) of the Movement Disorders Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS Part III in early-stage Parkinson's disease…
  • 2022 International Congress

    Childhood Trauma and Parkinson’s Disease: Associations of Adverse Childhood Experiences, Disease Severity and Quality of Life

    I. Subramanian, B. Mcdaniels, J. Farahnik, L. Mischley (Los Angeles, USA)

    Objective: Objective: The goal of this study was to survey individuals with PD to evaluate whether intensity of childhood trauma is associated with individual symptoms,…
  • 2022 International Congress

    Outcome and mortality of hospital admission with COVID-19 in parkinsonian syndromes

    L. Sorrell, A. Barnett, A. King, J. Inches, J. Rideout, J. Sneyd, C. Kobylecki, K. Chaudhuri, R. Walker, H. Martin, K. Stevens, S. Campbell, C. Carroll (Plymouth, United Kingdom)

    Objective: To evaluate features associated with poor outcome and mortality of COVID-19 in people with Parkinson’s disease (PD) and atypical Parkinsonian syndromes (APS) in a…
  • 2022 International Congress

    Robust methods for missing covariates in longitudinal studies with application to biomarker research in Parkinson’s disease dementia

    L. Suttner, P. Zhang, S. Xie (Philadelphia, USA)

    Objective: We propose a nonparametric method for handling different types of missing covariates in longitudinal studies. We show that the proposed method outperforms multiple standard…
  • 2022 International Congress

    Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model

    YE. Kim, TT. Lai, F. Richter, HI. Ma (Anyang, Republic of Korea)

    Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…
  • 2022 International Congress

    Machine learning supervised classification study for Parkinson`s disease progression through graph-based feature selection method

    V. Rama Raju, G. Ramaraju, V. Ramaraju (hyderabad, India)

    Objective: The model helps neuro physicians/ neurologists to improve the PD symptoms, or therapeutic-treatment planning-procedures. Background: Artificial intelligence-based machine learning (AI-ML) supervised classification systems have…
  • « Previous Page
  • 1
  • …
  • 352
  • 353
  • 354
  • 355
  • 356
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley